Thermosensitive in situ nanogel as ophthalmic delivery system of curcumin: development, characterization, in vitro permeation and in vivo pharmacokinetic studies
- PMID: 26024239
- DOI: 10.3109/10837450.2015.1026607
Thermosensitive in situ nanogel as ophthalmic delivery system of curcumin: development, characterization, in vitro permeation and in vivo pharmacokinetic studies
Abstract
Context: The nanogel combining cationic nanostructured lipid carriers (CNLC) and thermosensitive gelling agent could enhance preocular retention and ocular permeation capacity of curcumin (CUR).
Objective: The purpose of the study was to develop and characterize a thermosensitive ophthalmic in situ nanogel of CUR-CNLC (CUR-CNLC-GEL) and evaluate in vitro and in vivo properties of the formulations.
Materials and methods: The physicochemical properties, in vitro release and corneal permeation, were evaluated. Ocular irritation and preocular retention capacity were also conducted. Finally, pharmacokinetic study in the aqueous humor was investigated by microdialysis technique.
Results: The solution-gel transition temperature of the optimized formulation diluted by simulated tear fluid was 34 ± 1.0 °C. The CUR-CNLC-GEL displayed zero-order release kinetics. The apparent permeability coefficient (Papp) and the area under the curve (AUC0→∞) of CUR-CNLC-GEL were 1.56-fold and 9.24-fold, respectively, than those of curcumin solution (CUR-SOL, p < 0.01). The maximal concentration (Cmax) was significantly improved (p < 0.01). The prolonged mean residence time (p < 0.01) indicated that CUR-CNLC-GEL is a controlled release formulation.
Discussion and conclusion: Those results demonstrated that CUR-CNLC-GEL could become a potential formulation for increasing the bioavailability of CUR in the aqueous humor by enhancing corneal permeation and retention capacity.
Keywords: Cationic nanostructured lipid carriers; microdialysis; ocular drug delivery; pharmacokinetics; thermosensitive in situ nanogel.
Similar articles
-
Potential advantages of a novel chitosan-N-acetylcysteine surface modified nanostructured lipid carrier on the performance of ophthalmic delivery of curcumin.Sci Rep. 2016 Jun 28;6:28796. doi: 10.1038/srep28796. Sci Rep. 2016. PMID: 27350323 Free PMC article.
-
Novel in situ gel systems based on P123/TPGS mixed micelles and gellan gum for ophthalmic delivery of curcumin.Colloids Surf B Biointerfaces. 2015 Apr 1;128:322-330. doi: 10.1016/j.colsurfb.2015.02.007. Epub 2015 Feb 11. Colloids Surf B Biointerfaces. 2015. PMID: 25707750
-
A comparative study on the efficiency of chitosan-N-acetylcysteine, chitosan oligosaccharides or carboxymethyl chitosan surface modified nanostructured lipid carrier for ophthalmic delivery of curcumin.Carbohydr Polym. 2016 Aug 1;146:435-44. doi: 10.1016/j.carbpol.2016.03.079. Epub 2016 Mar 29. Carbohydr Polym. 2016. PMID: 27112894
-
The Role of Surface Active Agents in Ophthalmic Drug Delivery: A Comprehensive Review.J Pharm Sci. 2019 Jun;108(6):1923-1933. doi: 10.1016/j.xphs.2019.01.016. Epub 2019 Jan 23. J Pharm Sci. 2019. PMID: 30684539 Review.
-
In situ gel systems as 'smart' carriers for sustained ocular drug delivery.Expert Opin Drug Deliv. 2012 Apr;9(4):383-402. doi: 10.1517/17425247.2012.665367. Expert Opin Drug Deliv. 2012. PMID: 22432690 Review.
Cited by
-
Research progress of in-situ gelling ophthalmic drug delivery system.Asian J Pharm Sci. 2019 Jan;14(1):1-15. doi: 10.1016/j.ajps.2018.04.008. Epub 2018 May 24. Asian J Pharm Sci. 2019. PMID: 32104434 Free PMC article. Review.
-
Enhancing Therapeutic Efficacy of Curcumin: Advances in Delivery Systems and Clinical Applications.Gels. 2023 Jul 25;9(8):596. doi: 10.3390/gels9080596. Gels. 2023. PMID: 37623051 Free PMC article. Review.
-
Curcumin, A Potential Therapeutic Candidate for Anterior Segment Eye Diseases: A Review.Front Pharmacol. 2017 Feb 14;8:66. doi: 10.3389/fphar.2017.00066. eCollection 2017. Front Pharmacol. 2017. PMID: 28261099 Free PMC article. Review.
-
Recent Advancements in Nanopharmaceuticals for Novel Drug Delivery Systems.Pharm Nanotechnol. 2025;13(2):271-286. doi: 10.2174/0122117385324246240826042254. Pharm Nanotechnol. 2025. PMID: 39323341 Review.
-
Nanotechnology-based formulations to amplify intraocular bioavailability.Ther Adv Ophthalmol. 2022 Jul 18;14:25158414221112356. doi: 10.1177/25158414221112356. eCollection 2022 Jan-Dec. Ther Adv Ophthalmol. 2022. PMID: 35873277 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources